Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.10 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: quetmolimab | 0.81 |
| trials ClinicalTrials.gov | 3 Parkinson's trials, 0 stopped | 1.00 |
| literature PubMed | 45 Parkinson's papers of 2,202 | 0.50 |
| pathways Reactome | 2 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 2685
Sealed predictions
- CX3CL1 in dopamine neurons, braak-0.45 (p 0.219) → -0.55 (p 0.121)receipt 2693
Swarm cases
receipt 2693: CX3CL1 in dopamine neurons, braak
- power
- full sample -0.49 (p 0.037, n 18), 95% CI -0.78 to -0.04. the interval excludes zero: something may be there, smaller than a half can see.
- confounder
- adjusted for sex: -0.53 (p 0.023, n 18). holds up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.77 (p 2.1e-4, n 18). not the mix.
- skeptic
- leave-one-out range -0.60 to -0.43, sign flips 0; without severely affected donors -0.49 (p 0.037, n 18). robust.
- cell type
- strongest in astrocytes: -0.69 (p 0.0016, n 18) vs -0.49 in dopamine neurons. proposing astrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CX3CL1 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up CX3CL1 · astrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.25 p 0.374 (needs p < 6.7e-4)
Receipts
loading the receipts